AMBIJECT

Welcome to the Brand page for “AMBIJECT”, which is offered here for Pharmaceutical preparations, biopharmaceuticals based on human monoclonal antibodies for the treatment of immune and inflammatory diseases and disorders, cardiovascular diseases and disorders, metabolic diseases and disorders, and infectious-related diseases and disorders;syringes for medical purposes and for injections, excluding syringes for the treatment of central nervous system disorders including multiple sclerosis;.

Its status is currently believed to be active. Its class is unavailable. “AMBIJECT” is believed to be currently owned by “Johnson & Johnson”.